Objective: This paper discusses the evolution of pervasive healthcare from its inception for
activity recognition using wearable sensors to the future of sensing implant deployment and …

Natural heterogeneity in patient populations can make it very hard to develop treatments that
benefit all patients. As a result, an important goal of precision medicine is identification of …

It is well known that both the direction and magnitude of the treatment effect in clinical trials
are often affected by baseline patient characteristics (generally referred to as biomarkers) …

Background Tralokinumab is an anti-interleukin-13 human monoclonal antibody developed
for the treatment of severe, uncontrolled asthma. These clinical trials aimed to assess the …

The identification of patient subgroups with differential treatment effects is the first step
towards individualised treatments. A current draft guideline by the EMA discusses potentials …

Motivated by personalized decision making, given observational data {(xi, yi, zi)} i= 1 n
involving features xi∈ R d, assigned treatments or prescriptions zi∈{1,…, m}, and outcomes …

Precision medicine has revolutionised cancer treatments; however, actionable biomarkers
remain scarce. To address this, we develop the Oncology Biomarker Discovery (OncoBird) …

Motivation The identification of biomarkers to support decision-making is central to
personalized medicine, in both clinical and research scenarios. The challenge can be seen …

Important objectives in the development of stratified medicines include the identification and
confirmation of subgroups of patients with a beneficial treatment effect and a positive benefit …

Background It is well recognized that treatment effects may not be homogeneous across the
study population. Subgroup analyses constitute a fundamental step in the assessment of …